Cue Biopharma (CUE) Shareholder's Equity Growth (1y) (2018 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cue Biopharma | 449.73 Mn | 422.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.05% |
| Sep 30, 2025 | -47.78% |
| Jun 30, 2025 | -16.02% |
| Mar 31, 2025 | -78.09% |
| Dec 31, 2024 | -52.81% |
| Sep 30, 2024 | -40.55% |
| Jun 30, 2024 | -53.00% |
| Mar 31, 2024 | -45.40% |
| Dec 31, 2023 | -43.54% |
| Sep 30, 2023 | -15.95% |
| Jun 30, 2023 | -23.01% |
| Mar 31, 2023 | -14.93% |
| Dec 31, 2022 | 0.29% |
| Sep 30, 2022 | -20.08% |
| Jun 30, 2022 | -18.04% |
| Mar 31, 2022 | -7.17% |
| Dec 31, 2021 | -17.01% |
| Sep 30, 2021 | -27.45% |
| Jun 30, 2021 | -9.04% |
| Mar 31, 2021 | 54.01% |
| Dec 31, 2020 | 44.57% |
| Sep 30, 2020 | 224.01% |
| Jun 30, 2020 | 295.24% |
| Mar 31, 2020 | 82.86% |
| Dec 31, 2019 | 60.68% |
| Sep 30, 2019 | -31.42% |
| Jun 30, 2019 | -58.81% |
| Mar 31, 2019 | -55.22% |
| Dec 31, 2018 | -44.86% |